These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 27080840)

  • 1. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [From pharmacovigilance to pharmacoepidemiology and risk coordination].
    Montastruc JL
    Rev Med Interne; 2009 Dec; 30 Suppl 4():S281-90. PubMed ID: 19892443
    [No Abstract]   [Full Text] [Related]  

  • 4. Diverging approaches of pharmacovigilance and pharmacoepidemiology to assessing drug safety: epistemological and ethical implications.
    Coste J
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):600-602. PubMed ID: 28239922
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacovigilance - The next chapter.
    Moore N; Berdaï D; Blin P; Droz C
    Therapie; 2019 Dec; 74(6):557-567. PubMed ID: 31623850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interest of pharmacoepidemiology in pharmacovigilance: Post-authorization safety studies in regulatory pharmacovigilance activity.
    Abou Taam M; Ferard C; Rocle P; Maison P
    Therapie; 2019 Apr; 74(2):301-306. PubMed ID: 30704766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.
    Maignen F; Hauben M; Hung E; Van Holle L; Dogne JM
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):195-207. PubMed ID: 24243665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia.
    ; Andersen M; Bergman U; Choi NK; Gerhard T; Huang C; Jalbert J; Kimura M; Kimura T; Kubota K; Lai EC; Ooba N; Park BJ; Pratt N; Roughead EE; Sato T; Setoguchi S; Shin JY; Sundström A; Yang YH
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):700-4. PubMed ID: 23653370
    [No Abstract]   [Full Text] [Related]  

  • 9. Sample size of the reference sample in a case-augmented study.
    Ghosh P; Dewanji A
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):528-534. PubMed ID: 28295862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automatic detection of adverse events to predict drug label changes using text and data mining techniques.
    Gurulingappa H; Toldo L; Rajput AM; Kors JA; Taweel A; Tayrouz Y
    Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1189-94. PubMed ID: 23935003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database.
    Park K; Soukavong M; Kim J; Kwon KE; Jin XM; Lee J; Yang BR; Park BJ
    Yonsei Med J; 2017 May; 58(3):564-569. PubMed ID: 28332362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs.
    Lapeyre-Mestre M; Montastruc F
    Therapie; 2019 Apr; 74(2):209-214. PubMed ID: 30792079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacoepidemiology: lights and shadows].
    Laporte JR; Diogene E
    Bull Acad Natl Med; 2015; 199(2-3):281-8. PubMed ID: 27476310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.
    Fukazawa C; Hinomura Y; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1402-1408. PubMed ID: 30324671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies.
    Lai EC; Pratt N; Hsieh CY; Lin SJ; Pottegård A; Roughead EE; Kao Yang YH; Hallas J
    Eur J Epidemiol; 2017 Jul; 32(7):567-582. PubMed ID: 28698923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance: methods, recent developments and future perspectives.
    Härmark L; van Grootheest AC
    Eur J Clin Pharmacol; 2008 Aug; 64(8):743-52. PubMed ID: 18523760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacovigilance in the pharmaceutical industry.
    Talbot JC; Nilsson BS
    Br J Clin Pharmacol; 1998 May; 45(5):427-31. PubMed ID: 9643613
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.
    Vermeer NS; Ebbers HC; Straus SM; Leufkens HG; Egberts TC; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):297-306. PubMed ID: 26676881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement network.
    Cederholm S; Hill G; Asiimwe A; Bate A; Bhayat F; Persson Brobert G; Bergvall T; Ansell D; Star K; Norén GN
    Drug Saf; 2015 Jan; 38(1):87-100. PubMed ID: 25539877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.